Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

Abstract

Surgical bypass of peripheral arterial occlusive disease with autologous vein grafts provides an effective means of restoring blood flow to the lower extremity, and has been a standard therapy for patients with disabling claudication or critical limb ischemia (CLI). However, failure rates may run as high as 50% within 5 years.

These graft failures occur as a result of neointimal hyperplasia, a ubiquitous biologic response of blood vessel walls to injury, which is characterized by the migration and proliferation of smooth muscle cells (SMC). The E2F family of transcription factors regulates the expression of genes controlling SMC proliferation. Edifoligide (E2F Decoy) is a novel therapy that inhibits E2F function, thus attenuating neointimal hyperplasia. Its use in conjunction with a patented drug delivery pressurization chamber is under investigation. Using this system, edifoligide is administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation, resulting in minimal systemic drug exposure and excellent patient compliance.

This Phase 3, randomized, double-blind, multicenter clinical trial is designed to evaluate the safety and efficacy of edifoligide in a population of approximately 1400 patients with CLI undergoing infrainguinal bypass for peripheral arterial disease (PAD). The primary outcome measure will be the time to occurrence of non-technical graft failure resulting in either graft revision or major amputation at 12 months after enrollment. A governing Clinical Events Classification committee (CEC) will adjudicate each graft failure to determine its etiology.

The PREVENT III trial is the largest multicenter trial ever performed in patients receiving autologous vein bypass grafts for CLI. This landmark study will determine if edifoligide is safe and effective at preventing vein graft failure in patients undergoing lower extremity bypass, but it also provides a unique opportunity to observe current treatment practices in vascular surgery.

Get full access to this article

View all access options for this article.

References

Whittemore AD , Belkin M : Infrainguinal bypass. In: Vascular Surgery, vol. 1, ed. by Rutherford R . Philadelphia: WB Saunders, 1995, pp 794-814.

Bandyk DF , Schmitt DD , Seabrook GR , et al: Monitoring functional patency of in situ saphenous vein bypasses: The impact of a surveillance protocol and elective revision. J Vasc Surg 9:286-296, 1989.

Taylor LM , Porter JM : Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation 83(2 suppl):I63-I69, 1991.

Conte MS , Belkin M , Upchurch GR , et al: Impact of increasing comorbidity on infrainguinal reconstruction: A 20-year perspective. Ann Surg 233:445-452, 2001.

Cox JL , Chiasson DA , Gotlieb AI : Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Progr Cardiovasc Dis XXXIV(July–Aug):45-68, 1991.

Mann MJ , Dzau VJ : Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106:1071-1075, 2000.

Ehsan A , Mann MJ , Dell'Acqua G , et al: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121:714-722, 2001.

Mann MJ , Whittemore AD , Donaldson MC , et al: Exvivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomized, controlled trial. Lancet 354:1493-1498, 1999.

Grube E , Felderhoff T , Fitzgerald PJ , et al: Genetic manipulation of human coronary artery bypass grafts with E2F decoy (cgt003) reduces clinical graft failure — results of the randomized, controlled PREVENT II trial (abstract). Late Breaking Clinical Trials, American Heart Association, Nov. 2001.

10.

Jackson MR , Clagett GP : Antithrombotic therapy in peripheral arterial occlusive disease. Chest 114:666S-682S, 1998.

11.

Belkin M , Conte MS , Donaldson MC , et al: The impact of gender on the results of arterial bypass with in situ greater saphenous vein. Am J Surg 170:97-102, 1995.

12.

The SYNERGY Executive Committee . The SYNERGY trial: Study design and rationale. Superior yield of the new strategy of enoxaparin, revascularization, and glycoprotein IIb/IIIa inhibitors. Am Heart J 143:952-960, 2003.

13.

Dhainaut, JF , Laterre PF , LaRosa SP , et al: The clinical evaluation committee in a large multi-center Phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 31:2291-2301, 2003.

14.

Higashida RT , Furlan AJ : Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 34:e109-e137, 2003.